Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1, Multicenter, Open-label Study of BMS-986515, Healthy Donor Allogeneic CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases

The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-…

Refractory Autoimmune Diseases

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07115745